Cidofovir
- Generic Name
- Cidofovir
- Brand Names
- Vistide
- Drug Type
- Small Molecule
- Chemical Formula
- C8H14N3O6P
- CAS Number
- 113852-37-2
- Unique Ingredient Identifier
- 768M1V522C
- Background
Cidofovir is an injectable antiviral medication employed in the treatment of cytomegalovirus (CMV) retinitis in patients diagnosed with AIDS. It suppresses CMV replication through selective inhibition of viral DNA synthesis. It was manufactured by Gilead and initially approved by the FDA in 1996, but has since been discontinued.
- Indication
用于治疗免疫功能缺陷患者不能耐受更昔洛韦和膦甲酸钠治疗或治疗无效的巨细胞病毒感染。
- Associated Conditions
- Cytomegalovirus Retinitis, Herpes Simplex Virus, Monkeypox, Variola Major (Smallpox)
- Associated Therapies
- -
A Prolongation of a Clinical Study to Evaluate the Efficacy of an Aqueous Gel Containing 2% (w/w) of Cidofovir, Directly Applied on the Cervix Exhibiting High Grade Squamous Intraepithelial Lesions.
- Conditions
- Interventions
- First Posted Date
- 2016-11-30
- Last Posted Date
- 2016-11-30
- Lead Sponsor
- Brugmann University Hospital
- Target Recruit Count
- 36
- Registration Number
- NCT02976987
- Locations
- 🇧🇪
CHU Brugmann Hospital, Brussels, Belgium
Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
- Conditions
- Interventions
- First Posted Date
- 2016-10-13
- Last Posted Date
- 2021-11-03
- Lead Sponsor
- Shire
- Target Recruit Count
- 352
- Registration Number
- NCT02931539
- Locations
- 🇺🇸
University of Maryland, Baltimore, Maryland, United States
🇺🇸Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸University of Southern California, Los Angeles, California, United States
Intralesional Cidofovir for the Treatment of Recalcitrant Warts in the Pediatric Immune-suppressed Population.
- First Posted Date
- 2015-10-02
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- University of Minnesota
- Registration Number
- NCT02567149
- Locations
- 🇺🇸
University of Minnesota Medical Center, Minneapolis, Minnesota, United States
Bevacizumab Versus Cidofovir for the Treatment of Recurrent Respiratory Papillomatosis
- Conditions
- Interventions
- First Posted Date
- 2015-09-22
- Last Posted Date
- 2016-07-26
- Target Recruit Count
- 36
- Registration Number
- NCT02555800
- Locations
- 🇲🇽
Centro de Investigacion en Enfermedades Infecciosas, Mexico, Mexico
Modulation of the Expression of Papillomavirus (HPV) Oncoproteins to Major the Radiosensitivity: Trial Combining an Antiviral Agent VISTIDE and Radiochemotherapy in Cervical Cancers
- Conditions
- Interventions
- First Posted Date
- 2015-08-05
- Last Posted Date
- 2016-06-09
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 15
- Registration Number
- NCT02515877
- Locations
- 🇫🇷
Gustave Roussy Cancer Campus Grand Paris, Villejuif, Val de Marne, France
Intravesical Cidofovir for Hemorrhagic Cystitis
- Conditions
- Interventions
- First Posted Date
- 2013-03-22
- Last Posted Date
- 2016-12-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT01816646
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Cidofovir Versus Best Supportive Care for Hemorrhagic Cystitis
- Conditions
- Interventions
- First Posted Date
- 2011-02-14
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 27
- Registration Number
- NCT01295645
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Cidofovir Instillation in Hematopoietic Stem Cell Transplant (HSCT) Recipients With Hemorrhagic Cystitis
- First Posted Date
- 2009-08-11
- Last Posted Date
- 2019-05-14
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT00956176
Cidofovir in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer Who Are Receiving Chemotherapy and Radiation Therapy
- Conditions
- First Posted Date
- 2008-12-19
- Last Posted Date
- 2010-01-28
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 24
- Registration Number
- NCT00811408
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, France
Cidofovir in Treating HIV-Infected Patients With High-Grade Squamous Intraepithelial Lesions of the Skin Near the Anus
- First Posted Date
- 2007-10-30
- Last Posted Date
- 2015-12-21
- Lead Sponsor
- AIDS Malignancy Consortium
- Target Recruit Count
- 33
- Registration Number
- NCT00550589
- Locations
- 🇺🇸
UCLA Clinical AIDS Research and Education (CARE) Center, Los Angeles, California, United States
🇺🇸Boston University Cancer Research Center, Boston, Massachusetts, United States
🇺🇸Benaroya Research Institute at Virginia Mason Medical Center, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.